Table 1.
Dosing and therapeutic characteristics of new drugs approved in DS.
| Drug | Dose | Adverse Events | Monitoring | Special Warnings | ||
|---|---|---|---|---|---|---|
| Starting | Target | Max | ||||
| STP | 10–15 mg/kg | Up to 50 mg/kg, average 25–30 mg/kg | 3000 mg/d or 50 mg/kg |
Decreased appetite and weight Insomnia Somnolence |
CBC Liver function Weight |
Neutropenia and thrombocytopenia |
| FFA | 0.2 mg/kg | 0.7 mg/kg/without STP 0.4 mg/kg/with STP |
26 mg/d without STP 17 mg/d with STP |
Decreased appetite Diarrhea Pyrexia |
Echocardiography Weight |
Valvulopathy |
| CBD | 5 mg/kg | 10 mg/kg | 20 mg/kg | Somnolence Decreased appetite Diarrhea |
Liver function | Liver dysfunction, Somnolence |
Legend: STP—stiripentol, FFA—fenfluramine, CBD—cannabidiol.